Skip to main navigation Skip to search Skip to main content

Erratum: The antifungal and anti-pneumocystis activities of the novel compound A3IS (Mycosinate) (Antimicrobial Agents and Chemotherapy (2022) 66:8 (e00521-22) DOI: 10.1128/aac.00521-22)

  • Nathan P. Wiederhold
  • , Thomas F. Patterson
  • , Sandra Rebholz
  • , James Brennan
  • , Thomas Patton
  • , John Barrett
  • , Connell W.C. Boal
  • , Monika Ehrensberger
  • , Ryan Boyle
  • , Melanie T. Cushion
    • University of Texas Health Science Center at San Antonio
    • Department of Veterans Affairs
    • University of Cincinnati
    • VA Medical Center
    • Atlantic Technological University
    • Nektr Technologies Ltd.

    Research output: Contribution to journal › Comment/debate

    Abstract

    Volume 66, no. 8, e00521-22, 2022, https://doi.org/10.1128/aac.00521-22. James Brennan, Thomas Patton, and John Barrett were not included in the byline in the original article. The byline and affiliation line should appear as shown above.

    Original languageEnglish
    JournalAntimicrobial Agents and Chemotherapy
    Volume67
    Issue number2
    DOIs
    Publication statusPublished - Feb 2023

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Erratum: The antifungal and anti-pneumocystis activities of the novel compound A3IS (Mycosinate) (Antimicrobial Agents and Chemotherapy (2022) 66:8 (e00521-22) DOI: 10.1128/aac.00521-22)'. Together they form a unique fingerprint.

    Cite this